<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Holt, Hunter K.</style></author><author><style face="normal" font="default" size="100%">Gildengorin, Ginny</style></author><author><style face="normal" font="default" size="100%">Karliner, Leah</style></author><author><style face="normal" font="default" size="100%">Fontil, Valy</style></author><author><style face="normal" font="default" size="100%">Pramanik, Rajiv</style></author><author><style face="normal" font="default" size="100%">Potter, Michael B.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Differences in Hypertension Medication Prescribing for Black Americans and Their Association with Hypertension Outcomes</style></title><secondary-title><style face="normal" font="default" size="100%">The Journal of the American Board of Family
                Medicine</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">26-34</style></pages><doi><style  face="normal" font="default" size="100%">10.3122/jabfm.2022.01.210276</style></doi><volume><style face="normal" font="default" size="100%">35</style></volume><issue><style face="normal" font="default" size="100%">1</style></issue><abstract><style  face="normal" font="default" size="100%">Background: National guidelines recommend different pharmacologic management of hypertension (HTN) without comorbidities for Black/African Americans (BAA) compared with non-BAA. We sought to 1) identify if these recommendations have influenced prescription patterns in BAA and 2) identify the differences in uncontrolled HTN in BAA on different antihypertensive medications.Methods: We constructed a linked retrospective observational cohort using 2 years of electronic health records data, comprising of patients aged 18 to 85 with HTN on 1- or 2-drug regimens, including angiotensin-converting enzyme inhibitors (ACE), angiotensin receptor blockers (ARB), thiazide diuretics, or calcium channel blockers (CCB). We examined prescribing differences and HTN control in BAA versus non-BAA.Results: Among 10,875 patients identified, 20.6% were identified as BAA. 46.4% of BAA had uncontrolled HTN (≥140/90 mmHg) compared with 39.0% of non-BAA (P &lt; .001). 61.8% of BAA were treated with 1-drug compared with 68.4% of non-BAA. Of BAA on monotherapy: 41.3% were on thiazide, 40.1% on CCB, and 18.6% on ACE/ARB. Of non-BAA on monotherapy, 27.7% were on thiazide, 30.1% were on CCB, and 42.3% were on ACE/ARB. Of BAA patients on 1 drug, 45.2% had uncontrolled HTN compared with 38.0% of non-BAA (P &lt; .001). Of BAA on 2 drugs, 48.2% had uncontrolled HTN compared with 41.1% non-BAA (P &lt; .001). For each drug regimen, there was more variation in HTN control within each group than between BAA and non-BAA.Conclusions: Providers seem to be following race-based guidelines for HTN, yet HTN control for BAA remains worse than non-BAA. An individualized approach to HTN therapy for all patients may be more important than race-based guidelines.</style></abstract></record></records></xml>